Cargando…

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?

Pleuroparenchymal fibroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the fibrotic thickening of the visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with chest HRCT evidence of PPFE require...

Descripción completa

Detalles Bibliográficos
Autores principales: Bargagli, Elena, Mazzei, Maria Antonietta, Orlandi, Martina, Gentili, Francesco, Bellisai, Francesca, Frediani, Bruno, Bergantini, Laura, Carobene, Loredana, Randone, Silvia Bellando, Guiducci, Serena, Cameli, Paolo, Bruni, Cosimo, Cerinic, Marco Matucci
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617070/
https://www.ncbi.nlm.nih.gov/pubmed/31261523
http://dx.doi.org/10.1097/MD.0000000000016086
Descripción
Sumario:Pleuroparenchymal fibroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the fibrotic thickening of the visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with chest HRCT evidence of PPFE require close and recurrent follow-up with periodic evaluation of lung function parameters, DLCO and chest HRCT. Rheumatologists should be aware of this new radiological finding which is accompanied by a negative prognosis, especially when associated with a progressive course. Patients with this radiological pattern need to be monitored with particular attention.